Compare Ascendis Pharma A/S (ASND) vs McDonald's Corp (MCD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs McDonald's Corp — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while McDonald's Corp trades at $276.41 (market cap $195.10B). The key difference: McDonald's Corp is far larger — about 11× Ascendis Pharma A/S's market cap, and McDonald's Corp pays a 2.71% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | MCD | |
|---|---|---|
Market Cap | $17.74B | $195.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $341.06 |
52-Week Low | $163.32 | $264.54 |
Enterprise Value | $18.11B | $248.82B |
Volume | — | 2,230,036 |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
McDonald's (MCD) trades at $274.60, down 0.68% for the day, amid a bearish technical signal and mixed earnings history. The company reported Q1 2026 EPS of $2.83, beating expectations, but missed in Q3 2025. Revenue growth is steady, with 2025 revenue at $26.89B and net income of $8.56B, though long-term debt remains elevated at $38.42B. Recent news highlights a new global growth strategy, 'McDonald's NEXT', focusing on automation and menu improvements to counter competitive pressures.
The outlook is cautiously optimistic, with a consensus price target of $325.50 implying significant upside. Strengths include strong brand loyalty and consistent profitability, but risks include inflation impacting franchisee margins and high debt levels. Analyst sentiment is predominantly bullish, with 59.68% recommending buy, though technical indicators suggest near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →
